Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecanLaura Alder, Sarah Sammons, Dario Trapani et al.|npj Breast Cancer|2023Cited by 50
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mustafa Khasraw, Priscilla K. Brastianos et al.|The Lancet Oncology|2023Cited by 26
Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)Paolo Tarantino, Sara M. Tolaney, Melissa E. Hughes et al.|Cancer Research|2024Cited by 11
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancerLaura Noteware, Sarah Sammons, Gloria Broadwater et al.|Breast Cancer Research and Treatment|2022Cited by 6
Abstract 5257: Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd)Laura Alder, Sarah Sammons, Dario Trapani et al.|Cancer Research|2022Cited by 5